Physician profile
William E Behrens
NPI 1841291564
$1,942.25
in general payments reported to CMS, 2019-2025
22 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $26.32 · 2021: $165 · 2022: $295 · 2023: $419 · 2024: $671 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.79 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Pfizer INC. | $180.27 | 2019-2025 | |
| Amgen INC. | $179.94 | 2019-2023 | Prolia, Evenity |
| Abbott Laboratories | $178.89 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $157.57 | 2020-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $113.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $99.22 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $72.59 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $62.54 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $62.04 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.95 | 2022-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $39.66 | 2021 | |
| Neos Therapeutics, LP | $30.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.21 | 2024 | Capvaxive, Vaxelis, Gardasil |
| Otsuka America Pharmaceutical, INC. | $23.59 | 2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.02 | 2019 | |
| Lilly USA, LLC | $20.51 | 2024 | Jardiance |
| Quidel Corporation | $20.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.51 | 2022 | |
| Therapeuticsmd, INC. | $13.87 | 2019 | |
| Tms Neurohealth Centers INC. | $13.03 | 2025 | Tms Neurohealth Centers INC. |
| Arbor Pharmaceuticals, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Behrens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.